Drug-resistant tuberculosis (DRTB) accounts for 4% of new TB morbidity, with rifampicin resistance accounting for 25% of antimicrobial resistance-related mortality globally. Over time, there has been increased resistance in Kenya with possible community spread of resistant strains, thereby necessitating robust DRTB surveillance. This study shares Kenya's experience in utilizing DRTB data.